Resources
175 Results (showing 61 - 70)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/4/2020 (updated 4/3/2024)
The opioid crisis has disproportionally affected Appalachia. One of the potentially
lethal and costly complications associated with IV drug use is infective endocarditis (IE). The goal of this study was to assess the trend and costs of substance abuse associated IE admissions in Southern West Virginia.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Adverse childhood experiences, known as ACEs, are defined by the Centers for Disease Control and Prevention as "potentially traumatic events that occur in childhood." One common example is experienced by children growing up in a household with parents engaged in substance use. This publication is the first in a two-part series addressing the relationship between ACEs and substance use throughout the life cycle, covering substance use as an ACE from infancy through adolescence.